{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T09:44:33Z","timestamp":1751449473630,"version":"3.40.3"},"reference-count":16,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2025]]},"DOI":"10.3960\/jslrt.24048","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T22:10:06Z","timestamp":1743113406000},"page":"55-61","source":"Crossref","is-referenced-by-count":1,"title":["ALK-negative anaplastic large cell lymphoma with &lt;i&gt;TP53&lt;\/i&gt; mutation developing during the administration of baricitinib for atopic dermatitis \u2013 A case report \u2013"],"prefix":"10.3960","volume":"65","author":[{"given":"Hidetsugu","family":"Kawai","sequence":"first","affiliation":[{"name":"Department of Hematology \/ Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shino","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Hematology \/ Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sawako","family":"Shiraiwa","sequence":"additional","affiliation":[{"name":"Department of Hematology \/ Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Miyaoka","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tokai University School of Medicine, Isehara, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ogiya","sequence":"additional","affiliation":[{"name":"Department of Hematology \/ Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Toyosaki","sequence":"additional","affiliation":[{"name":"Department of Hematology \/ Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Machida","sequence":"additional","affiliation":[{"name":"Department of Hematology \/ Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikio","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hematology \/ Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Onizuka","sequence":"additional","affiliation":[{"name":"Department of Hematology \/ Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Hematology \/ Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tokai University School of Medicine, Isehara, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kawada","sequence":"additional","affiliation":[{"name":"Department of Hematology \/ Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Bieber T, Katoh N, Simpson EL <i>et al.<\/i> Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. J Dermatolog Treat. 2023; 34: 2161812.","DOI":"10.1080\/09546634.2022.2161812"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Swerdlow SH, Campo E, Pileri SA <i>et al.<\/i> The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127: 2375-2390.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Morris SW, Kirstein MN, Valentine MB <i>et al.<\/i> Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma. Science. 1994; 263: 1281-1284.","DOI":"10.1126\/science.8122112"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Zhang XR, Chien PN, Nam SY, Heo CY. Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment. Cancers (Basel). 2022; 14: 1650.","DOI":"10.3390\/cancers14071650"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Lobello C, Tichy B, Bystry V <i>et al.<\/i> STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma. Leukemia. 2021; 35: 1500-1505.","DOI":"10.1038\/s41375-020-01093-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Crescenzo R, Abate F, Lasorsa E <i>et al.<\/i> Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015; 27: 516-532.","DOI":"10.1016\/j.ccell.2015.03.006"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Wan J, Shin DB, Syed MN <i>et al.<\/i> Malignancy risk in patients with atopic dermatitis: a population-based cohort study. Br J Dermatol. 2023; 189: 53-61.","DOI":"10.1093\/bjd\/ljad072"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Xiang C, Wu W, Fan M <i>et al.<\/i> Phosphorylated STAT3 as a potential diagnostic and predictive biomarker in ALK- ALCL vs. CD30high PTCL, NOS. Front Immunol. 2023; 14: 1132834.","DOI":"10.3389\/fimmu.2023.1132834"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Sekine Y, Tsuji S, Ikeda O <i>et al.<\/i> Regulation of STAT3-mediated signaling by LMW-DSP2. Oncogene. 2006; 25: 5801-5806.","DOI":"10.1038\/sj.onc.1209578"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Luchtel RA, Dasari S, Oishi N <i>et al.<\/i> Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood. 2018; 132: 1386-1398.","DOI":"10.1182\/blood-2018-03-838524"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Kanagal-Shamanna R, Beck DB, Calvo KR. Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy. Annu Rev Pathol. 2024; 19: 479-506.","DOI":"10.1146\/annurev-pathmechdis-051222-122724"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Moskowitz AJ, Ghione P, Jacobsen E <i>et al.<\/i> A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas. Blood. 2021; 138: 2828-2837.","DOI":"10.1182\/blood.2021013379"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Song Y, Yoon DH, Yang H <i>et al.<\/i> Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas. Ann Oncol. 2023; 34: 1055-1063.","DOI":"10.1016\/j.annonc.2023.08.013"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Chen S, Li C, Tu Z <i>et al.<\/i> Off-label use of Baricitinib improves moderate and severe atopic dermatitis in China through inhibiting MAPK and PI3K\/Akt\/mTOR pathway via targeting JAK-STAT signaling of CD4+ cells. Front Pharmacol. 2024; 15: 1324892.","DOI":"10.3389\/fphar.2024.1324892"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Palanichamy JK, Tran TM, King JK <i>et al.<\/i> Distinct oncogenic phenotypes in hematopoietic specific deletions of Trp53. Sci Rep. 2023; 13: 7490.","DOI":"10.1038\/s41598-023-33949-8"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Drakos E, Atsaves V, Schlette E <i>et al.<\/i> The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53. Leukemia. 2009; 23: 2290-2299.","DOI":"10.1038\/leu.2009.180"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/1\/65_24048\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T04:49:22Z","timestamp":1743223762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/1\/65_24048\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.24048","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"type":"print","value":"1346-4280"},{"type":"electronic","value":"1880-9952"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"24048"}}